Subscribe to our Newsletters !!
Fermentation is a natural method which is applied
Eppendorf and the journal Science are now
The human metapneumovirus, more simply referred to
We are truly honored to share that HiMedia Laborat
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Dear Readers, Welcome to the latest issue of Mi
AstraZeneca in June chose Emergent to assist make 300 million doses of its possible COVID-19 vaccine vowed to the USA.
AstraZeneca has signed manufacturing deals internationally to meet its goal of earning 2 billion gallons of this vaccine, for example with just two Bill Gates-backed ventures and a $1.2 billion deal with the US authorities.
The company’s vaccine, which is co-developed from the University of Oxford, is among the very first to move into mid-stage trials. There are no approved vaccines or treatments for COVID-19, the highly infectious respiratory illness brought on by the novel coronavirus.
The latest contract follows a $87 million deal in June where Emergent signed an agreement to become the growth partner for AstraZeneca’s COVID-19 vaccine candidate.
Activities under the agreement will likely be at Emergent’s Baltimore Bayview centre, the company said, which is a designated centre by the US Department of Health and Human Services for rapid manufacturing of large quantities of vaccines and treatments.
